Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan

References

• VosTFlaxmanADNaghaviMYears lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592163219623245607
   PubMed Web of Science ®Google Scholar
• FreynhagenRBaronRGockelUTölleTRpainDETECT: a new screening questionnaire to identify neuropathic components in patients with back painCurr Med Res Opin200622101911192017022849
   PubMed Web of Science ®Google Scholar
• DagenaisSCaroJHaldemanSA systematic review of low back pain cost of illness studies in the United States and internationallySpine J20088182018164449
   PubMed Web of Science ®Google Scholar
• StewartWFRicciJACheeEMorgansteinDLiptonRLost productive time and cost due to common pain conditions in the US workforceJAMA2003290182443245414612481
   PubMed Web of Science ®Google Scholar
• MehraMHillKNichollDSchadrackJThe burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysisJ Med Econ201215224525222136441
   PubMedGoogle Scholar
• NakamuraMNishiwakiYUshidaTToyamaYPrevalence and characteristics of chronic musculoskeletal pain in JapanJ Orthop Sci201116442443221678085
   PubMed Web of Science ®Google Scholar
• NakamuraMNishiwakiYSumitaniMInvestigation of chronic musculoskeletal pain (third report): with special reference to the importance of neuropathic pain and psychogenic painJ Orthop Sci201419466767524737064
   PubMed Web of Science ®Google Scholar
• FujiiTMatsudairaKPrevalence of low back pain and factors associated with chronic disabling back pain in JapanEur Spine J201322243243822868456
   PubMed Web of Science ®Google Scholar
• SukaMYoshidaKLow back pain deprives the Japanese adult population of their quality of life: a questionnaire survey at five healthcare facilities in JapanEnviron Health Prev Med200813210911519568889
   PubMedGoogle Scholar
• ItohHKitamuraFYokoyamaKEstimates of annual medical costs of work-related low back pain in JapanInd Health201351552452923955653
   PubMed Web of Science ®Google Scholar
• SadoskyABDiBonaventuraMCappelleriJCEbataNFujiiKThe association between lower back pain and health status, work productivity, and health care resource use in JapanJ Pain Res2015811913025750546
   PubMed Web of Science ®Google Scholar
• YamashitaTTakahashiKYonenobuKKikuchiSPrevalence of neuropathic pain in cases with chronic pain related to spinal disordersJ Orthop Sci2014191152124306580
   PubMed Web of Science ®Google Scholar
• DworkinRHO’ConnorABAudetteJRecommendations for the pharmacological management of neuropathic pain: an overview and literature updateMayo Clin Proc2010853 SupplS3S1420194146
   PubMed Web of Science ®Google Scholar
• Japan Society of Pain CliniciansGuideline for the Pharmacologic Management of Neuropathic PainTokyoShinko Trading Company Ltd, Publication Department of Medical Books2011 Available from: http://www.sshinko.com/?p=2690Accessed September 3, 2015
   Google Scholar
• FieldMJCoxPJStottEIdentification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalinProc Natl Acad Sci U S A200610346175371754217088553
   PubMed Web of Science ®Google Scholar
• SatohJYagihashiSBabaMEfficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trialDiabet Med201128110911621166852
   PubMed Web of Science ®Google Scholar
• OgawaSSuzukiMArakawaAEvaluation of the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia: a randomized, double-blind, multicenter, placebo-controlled studyJ Japan Soc Pain Clin2010172141152 Available from: https://www.jstage.jst.go.jp/article/jjspc/17/2/17_2_141/_article/-char/ja/Accessed September 3, 2015
   Google Scholar
• OnouchiKKogaHYokoyamaKYoshiyamaTAn open-label, long-term study examining the safety and tolerability of pregabalin in Japanese patients with central neuropathic painJ Pain Res2014743944725114584
   PubMed Web of Science ®Google Scholar
• IkedaSOgawaSHosokawaTCost-effectiveness analysis of pregabalin for treatment of peripheral neuropathic painJapanese Journal of Pharmacoepidemiology201116119
   Google Scholar
• TaguchiTIgarashiAWattSEffectiveness of pregabalin compared with usual care for the treatment of chronic low back pain with a neuropathic component in Japan; the patient’s perspectiveJ Pain Res2015848749726346468
   PubMed Web of Science ®Google Scholar
• HerdmanMGudexCLloydADevelopment and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Qual Life Res201120101727173621479777
   PubMed Web of Science ®Google Scholar
• IkedaSShiroiwaTIgarashiADeveloping a Japanese version of the EQ-5D-5L value setJournal of the National Institute of Public Health20156414755 Japanese
   Google Scholar
• ZelmanDDukesEBrandenburgNBostromAGoreMIdentification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathyPain20051151–2293615836967
   PubMed Web of Science ®Google Scholar
• SatohJYagihashiSBabaMSuzukiMArakawaAYoshiyamaTEfficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trialJ Diabetes Investig201126457463
   Web of Science ®Google Scholar
• OgawaSSuzukiMArakawaAYoshiyamaTSuzukiMLong-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose studyMasui2010598961970 Japanese20715519
   PubMedGoogle Scholar
• SimpsonDMRiceASEmirBA randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathyPain2014155101943195424907403
   PubMed Web of Science ®Google Scholar
• LoflandJHPizziLFrickKDA review of health-related workplace productivity loss instrumentsPharmacoeconomics200422316518414871164
   PubMed Web of Science ®Google Scholar
• WPAI:SHP V2.0 [webpage on the Internet]New YorkReilly Associates [updated August 18, 2010]. Available from: http://www.reillyassociates.net/WPAI_SHP.htmlAccessed January 16, 2015
   Google Scholar
• ToelleTVarvaraRNimourMEmirBBrasserMPregabalin in neuropathic pain related to DPN, cancer and back pain: analysis of a 6-week observational studyOpen Pain J20125111
   Google Scholar
• SaldañaMTNavarroAPérezCMasramónXRejasJPatient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settingsRheumatol Int20103081005101519798503
   PubMed Web of Science ®Google Scholar
• ChevalierPLamotteMVan CampenhoutHEyckermanRAnnemansLCost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in BelgiumJ Med Econ201316559660523409950
   PubMedGoogle Scholar
• Morera-DomínguezCCeberio-BaldaFFlórez-GarcíaMMasramónXLópez-GómezVA cost-consequence analysis of pregabalin versus usual care in the symptomatic treatment of refractory low back pain: sub-analysis of observational trial data from orthopaedic surgery and rehabilitation clinicsClin Drug Investig2010308517531
   Web of Science ®Google Scholar
• PérezCNavarroASaldañaMTFigueras-BalsellsMMuñoz-TuduríMRejasJCost savings associated with early initiation of pregabalin in the management of peripheral neuropathic painClin J Pain201329647147723328322
   PubMed Web of Science ®Google Scholar
• PrettyjohnsMSandelinRListerSNorrefalkJRA cost-utility study of the use of pregabalin added to usual care in refractory neuropathic pain patients in a Swedish settingJ Med Econ20121561097110922712872
   PubMedGoogle Scholar
• GordonJListerSPrettyjohnsMMcEwanPTetlowAGabrielZA cost-utility study of the use of pregabalin in treatment-refractory neuropathic painJ Med Econ201215220721822017236
   PubMedGoogle Scholar
• OhkusaYSugawaraTResearch for willingness to pay for one QALY gainJournal of Health Care and Society2006162157165 Japanese
   Google Scholar
• ShiroiwaTSungYKFukudaTLangHCBaeSCTsutaniKInternational survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?Health Econ201019442243719382128
   PubMed Web of Science ®Google Scholar
• ShiroiwaTIgarashiAFukudaTIkedaSWTP for a QALY and health states: more money for severer health states?Cost Eff Resour Alloc2013112224128004
   PubMedGoogle Scholar
• Guide to the Methods of Technology AppraisalLondonNational Institute for Health and Clinical Excellence2013 Available from: https://www.nice.org.uk/article/pmg9/chapter/forewordAccessed September 3, 2015
   Google Scholar
• NeumannPJCohenJTWeinsteinMCUpdating cost-effectiveness – the curious resilience of the $50,000-per-QALY thresholdN Engl J Med2014371979679725162885
   PubMed Web of Science ®Google Scholar
• TillingCKrolMTsuchiyaABrazierJExelJvBrouwerWDoes the EQ-5D reflect lost earnings?Pharmacoeconomics2012301476122066754
   PubMed Web of Science ®Google Scholar